Introduction {#sec1-1759091417742296}
============

Homocysteine is a nonprotein forming amino acid involved in the production of both methionine and cysteine. Mutations in the methylenetetrahydrofolate reductase or cystathionine beta synthase (CBS) genes or low levels of vitamins B6, B9, and B12 can lead to increased levels of plasma homocysteine ([@bibr20-1759091417742296]; [@bibr26-1759091417742296]; [@bibr25-1759091417742296]; [@bibr17-1759091417742296]; [@bibr5-1759091417742296]), termed hyperhomocysteinemia (HHcy). HHcy is a risk factor for both vascular cognitive impairment and dementia (VCID) and Alzheimer's disease (AD; [@bibr2-1759091417742296]; [@bibr7-1759091417742296]; [@bibr33-1759091417742296]). Previous studies have shown that serum homocysteine levels are inversely related to cognitive function in patients with dementia and elevated levels are more common in VCID patients than AD patients ([@bibr18-1759091417742296]; [@bibr6-1759091417742296]). While studies have shown an association between homocysteine levels and hippocampal atrophy, white matter lesions, and lacunar infarcts, the mechanism of homocysteine-induced damage remains unknown ([@bibr35-1759091417742296]; [@bibr8-1759091417742296]).

Our group has been working on HHcy induction in mice as a model of VCID. In both mouse and humans, 5 to 12 µM of homocysteine is considered normal, 12 to 30 µM is categorized as mild HHcy, 30 to 100 µM is moderate HHcy, and anything above 100 µM is considered severe HHcy. In C57BL/6 mice, dietary HHcy induction through deficiency in vitamins B6, B9, and B12 and enrichment in methionine results in homocysteine levels between 50 and 80 µM, thus inducing moderate HHcy ([@bibr30-1759091417742296]). Microhemorrhages were the main cerebrovascular pathology noted in the HHcy mice and behavior testing showed significant cognitive deficits in these mice. Moderate HHcy also induced a proinflammatory phenotype, reduced cerebral blood flow, and increased activity of matrix metalloproteinase 2 (MMP2) and MMP9, which are known to degrade tight junctions in the blood--brain barrier ([@bibr14-1759091417742296]).

Dietary induction of HHcy in amyloid precursor protein (APP)/PS1 mice produces a comorbidity mouse model with aspects of both AD and VCID ([@bibr31-1759091417742296]). During the radial arm water maze, the comorbidity mouse model displayed additive cognitive deficits. Clinically, it has been shown that comorbidity patients show an additive effect on test scores for memory and executive function, thus making this a clinically relevant model ([@bibr23-1759091417742296]). Induction of HHcy in APP/PS1 mice produced a switch from an anti-inflammatory phenotype to a proinflammatory phenotype and significantly increased MMP9 and MMP2 activity. While there were not significant changes in total Aβ levels, we did see a change in the location of Aβ, with more accumulating around the vasculature. Finally, these comorbidity mice had a significant increase in microhemorrhages.

It remains unclear from our *in vivo* studies what the effects of homocysteine are on the individual cell types of the brain, which could help us elucidate possible therapeutic targets. To determine the cell specific effects of HHcy, we took separate cultures of C8-D1A astrocytes, BV2 microglia cells, primary endothelial cells, and N2a neuronal cells and treated them with 50 µM of homocysteine for 24, 48, 72, and 96 hr. For each cell type, we analyzed the gene expression of several cell type specific markers, inflammatory markers, and MMP9 system markers.

Materials and Methods {#sec2-1759091417742296}
=====================

C8-D1A Cell Culture {#sec3-1759091417742296}
-------------------

C8-D1A cells were obtained directly from American Type Culture Collection (Catalogue No. CRL-2541, Manassas, VA). Cells were grown in 75 cm^2^ flasks in DME media containing 10% fetal bovine serum and 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA) until approximately 80% confluency was reached, usually after 7 days.

BV2 Cell Culture {#sec4-1759091417742296}
----------------

BV2 cells, originally developed by Elisabetta Blasi et al. ([@bibr1-1759091417742296]; courtesy of Dr. Linda Van Eldik), were grown in petri dishes in DME media with nutrient mixture F12 containing 10% fetal bovine serum, 1% serum L-glutamate, and 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA) until approximately 80% confluency was reached, usually after 3 days.

Primary Endothelial Cell Culture {#sec5-1759091417742296}
--------------------------------

C57BL/6 mouse primary brain microvascular endothelial cells were obtained directly from Cell Biologics (Catalogue No. C57-6023, Chicago, IL). Cells were grown in 75 cm^2^ flasks coated with a gelatin-based coating solution (Cell Biologics, Chicago, IL). Endothelial cell media containing vascular endothelial growth factor, endothelial cell growth supplement, heparin, epidermal growth factor, hydrocortisone, L-glutamine, an antibiotic-antimycotic solution, and fetal bovine serum (Complete Mouse Endothelial Cell Medium w/ Kit, Cell Biologics, Chicago, IL) was used to grow the endothelial cells to approximately 80% confluency.

N2a Cell Culture {#sec6-1759091417742296}
----------------

N2a cells (courtesy of Dr. John Gensel; [@bibr21-1759091417742296]) were grown in 75 cm^2^ flasks in Opti-MEM media containing 40% DME media, 10% fetal bovine serum, and 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA) until approximately 80% confluency was reached, usually after 3 days.

HHcy Treatment {#sec7-1759091417742296}
--------------

Once the cells reached 80% confluency, the cells were trypsinized and resuspended in 10 mL of media with serum. For the BV2 and N2a cells, 100 µL of cells were placed in each well of a six-well plate. For the C8-D1A cells, 500 µL of cells were placed in each well of a six-well plate. For the endothelial cells, 1 mL of cells were placed in a 25 cm^2^ flask coated with a gelatin-based coating solution (Cell Biologics, Chicago, IL). For all cells, the volume in each well or flask was brought up to 2 mL with media containing serum.

Once the cells reached 60% to 70% confluency, media with serum was replaced with serum-free media for 24 hr to avoid unwanted stimulation by serum components. To determine the optimal dose of HHcy, BV2 cells were treated with either 5 µM, 15 µM, 50 µM, or 100 µM of homocysteine (Sigma, St. Louis, MO) for 24 hr. Based on the results in [Figure 1(a)](#fig1-1759091417742296){ref-type="fig"}, 50 µM was used to treat all cell types since each cell would be exposed to the same levels *in vivo*. Figure 1.Homocysteine dose response and cell viability. Relative gene expression of (a) proinflammatory and (b) anti-inflammatory markers in BV2 microglial cells after 24 hr of treatment with homocysteine. Data are shown as a fold change from control-treated cells. Cell viability of (c) astrocytes, (d) microglia, (e) endothelial cells, and (f) neuronal cells after treatment with 50 µM of homocysteine for 48 and 96 hr. \*\* indicates a *p* value \< .01 compared with control-treated cells for that time point.

After 24 hr in serum-free media, each cell type was treated with either 50 µM homocysteine or remained in serum-free media as a control for 24, 48, 72, or 96 hr. Media was changed every 2 days. Media was aspirated and cells were rinsed in 1X DPBS (Life Technologies, Carlsbad, CA) and frozen at −20° until RNA isolation. Cell treatments were run at least twice for each cell line in groups of two or three (*N* = 4 to 6 per group).

Cell viability was determined at 48 and 96 hr for each cell type. The media from each well or flask was combined with the trypsinized cells and resuspended in 2 mL of media. After 500 µL of the resuspended cells was combined with 500 µL of trypan blue (Amresco, Solon, OH), 10 µL of this mixture was loaded on a hemocytometer. The number of dead and live cells were counted from four grids and averaged.

All cells were incubated at 5% CO~2~ at 37℃.

Quantitative Reverse Transcription Polymerase Chain Reaction {#sec8-1759091417742296}
------------------------------------------------------------

Total mRNA was extracted from the frozen cells using cells scrapers in lysis buffer from the RNeasy Mini-kit (Qiagen, Valencia, CA). The subsequent steps of the extraction were done according to the manufacturer's instructions. The Biospec-Nano Spectrophotometer (Shimadzu, Kyoto, Japan) was used to quantify the nucleic acid concentration of each sample. cDNA was transcribed using the High Capacity kit (ThermoFisher, Walthan, MA) according to the manufacturer's instructions. The cDNA was produced using the Veriti™ 96-well Thermocycler (Applied Biosystems, Grand Island, NY) through heating and annealing cycles.

Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) was performed using the Fast-TaqMan Gene Expression kit (Life Technologies, Carlsbad, CA) in 96-well plates. In each well, 1 µL of the appropriate gene probe (Life Technologies, Carlsbad, CA) listed in [Table 1](#table1-1759091417742296){ref-type="table"} was added to 10 µL of the Fast-TaqMan reagent along with 0.5 µL of cDNA and 6.5 µL of RNAse-free water for a final volume of 18 µL. Real-time RT-PCR was performed using the ViiA™7 Real-Time PCR system (Applied Biosystems, Grand Island, NY). All genes were normalized to the 18 S rRNA gene. Fold change was determined using the --ΔΔCt method and the homocysteine treated cells were compared with the control cells of the appropriate time point. Table 1.Genes for Real-Time PCR.Gene of interestPMIDTaqman IDIL1βNM_008361.3Mm.222830TNFαNM_013693.3Mm.1293IL1RaNM_031167.5Mm.882CD86NM_019388.3Mm.1452TGFβ1NM_011577.1Mm.248380MRC1NM_008625.2Mm.2019MMP3NM_010809.1Mm.4993MMP9NM_013599.3Mm.4406TIMP1NM_001044384.1Mm.8245AQP4NM_009700.2Mm.250786GFAPNM_001131020.1Mm.1239KCNJ10NM_001039484.1Mm.254563KCNMA1NM_001253358.1Mm.343607PECAM1AK037551.1Mm.343951CLDN5NM_013805.4Mm.22768OCEL1NM_008756.2Mm.4807COL4α5NM_001163155.1Mm.286892APPNM_001198823.1Mm.277585GRNNM_008175.4Mm.1568GSK3βNM_019827.6Mm.394930PPP2CANM_019411.4Mm.00479816

Analysis {#sec9-1759091417742296}
--------

Data are presented as mean ± SEM. Statistical analysis was performed using the JMP statistical analysis software program (SAS Institute, Cary, NC). Student's *t*-test were performed and statistical significance was assigned when the *p*-value was \< .05.

Results {#sec10-1759091417742296}
=======

To determine the dose response to homocysteine, BV2 cells were treated with 5, 15, 50, or 100 µM of homocysteine for 24 hr ([Figure 1(a)](#fig1-1759091417742296){ref-type="fig"} and ([b](#fig1-1759091417742296){ref-type="fig"})). Treatment of BV2 cells with 50 µM of homocysteine, which is considered moderate HHcy, resulted in the highest gene expression levels of several pro- and anti-inflammatory markers, specifically interleukin 1 beta (IL1β), interleukin 1 receptor antagonist (IL1Ra), cluster of differentiation 86 (CD86), and transforming growth factor beta 1 (TGFβ1); therefore, 50 µM was used uniformly across all cell types. Importantly, in our mice, we achieve 50 to 80 µM levels of homocysteine in plasma ([@bibr30-1759091417742296]; [@bibr36-1759091417742296]). Cell viability for each cell type was also determined after exposure to homocysteine for 48 or 96 hr. Astrocytes had a slight decrease in cell viability only at 48 hr, but this was not significant ([Figure 1(c)](#fig1-1759091417742296){ref-type="fig"}). At 48 hr, there was a slight increase in microglia cell viability when exposed to homocysteine, and this became significant by 96 hr ([Figure 1(d)](#fig1-1759091417742296){ref-type="fig"}). Endothelial cells had a significant increase in cell viability at 48 hr but decreased at 96 hr ([Figure 1(e)](#fig1-1759091417742296){ref-type="fig"}). At both 48 and 96 hr, neuronal cells had slight increases in cell viability after treatment with homocysteine; however, this was not significant ([Figure 1(f)](#fig1-1759091417742296){ref-type="fig"}). Most importantly, no significant cell death was observed with homocysteine treatment in any of the cell types studied.

We also determined changes in the gene expression of several pro- and anti-inflammatory markers when astrocytes, microglia, endothelial cells, and neuronal cells were exposed to homocysteine. Astrocytes show no significant changes in the proinflammatory marker tumor necrosis factor alpha (TNFα; [Figure 2(a)](#fig2-1759091417742296){ref-type="fig"}). However, there was a significant decrease in the anti-inflammatory marker IL1Ra at 48 hr when compared with controls. There was also an overall trend for decreased IL1Ra up to 72 hr, but levels increased again at 96 hr. The other anti-inflammatory marker, TGFβ1, was slightly increased at 48 hr but decreased at 72 hr. Figure 2.Neuroinflammation markers. Relative gene expression changes for pro- and anti-inflammatory markers in (a) astrocytes, (c) microglia, (e) endothelial cells, and (g) neuronal cells. Data are shown as a fold change from control-treated cells for that time point. \*indicates a *p* value \< .05 and \*\* indicates a *p* value \< .01 compared with control-treated cells for that time point. *p* values for homocysteine-treated comparisons for (b) astrocytes, (d) microglia, (f) endothelial cells, and (h) neuronal cells. Significant differences are shown in bold.

Microglia cells treated with homocysteine had a significant increase in the proinflammatory marker IL1β and a slight but nonsignificant increase in TNFα at 48 hr ([Figure 2(c)](#fig2-1759091417742296){ref-type="fig"}). There was also a significant increase in the anti-inflammatory marker TGFβ1 at 48 hr. Levels of IL1β, TNFα, and TGFβ1 were decreased at 72 hr and again at 96 hr when compared with 48 hr homocysteine-treated cells ([Figure 2(c)](#fig2-1759091417742296){ref-type="fig"} and ([d](#fig2-1759091417742296){ref-type="fig"})). At 72 hr, IL1Ra levels were significantly increased when compared with controls and when compared with 48 hr homocysteine-treated cells. Levels of IL1Ra were significantly decreased by 96 hr when compared with 72 hr homocysteine-treated cells. The other anti-inflammatory marker, CD86, had slight increases up to 72 hr and a decrease at 96 hr that was significantly different from the 72 hr homocysteine-treated cells.

Endothelial cells only had a significant decrease in the anti-inflammatory marker mannose receptor C Type 1 at 96 hr when compared with 48 hr homocysteine-treated cells ([Figure 2(e)](#fig2-1759091417742296){ref-type="fig"} and ([f](#fig2-1759091417742296){ref-type="fig"})).

Neuronal cells treated with homocysteine had a slight increase in TNFα at 48 hr but was only significant when compared with 24 hr homocysteine-treated cells ([Figure 2(g)](#fig2-1759091417742296){ref-type="fig"} and ([h](#fig2-1759091417742296){ref-type="fig"})). The anti-inflammatory markers (IL1Ra, CD86, and TGFβ1) showed increased levels with a significant peak at 72 hr when compared with controls. CD86 and TGFβ1 were significantly decreased at 96 hr when compared with 72 hr homocysteine-treated cells. It should be noted that while the fold changes for these inflammatory markers are dramatic, the qPCR cycle numbers were high, indicating the expression level was extremely low in these neuronal cells.

The MMP9 system has been implicated in the tight junction breakdown leading to microhemorrhages in AD and VCID; therefore, we assessed the changes in the gene expression levels of the MMP9 system markers in response to homocysteine. In astrocytes, there was a slight increase in MMP3 expression over 96 hr, but this was not significant ([Figure 3(a)](#fig3-1759091417742296){ref-type="fig"}). However, MMP9 expression was significantly increased at 48 hr when compared with controls. Levels of MMP9 were significantly decreased again at 72 and 96 hr when compared with the 48 hr treated homocysteine cells ([Figure 3(b)](#fig3-1759091417742296){ref-type="fig"}). Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) gene expression levels increased over time, with 96 hr being significantly increased when compared with controls and when compared with 24 and 48 hr homocysteine-treated cells. Figure 3.MMP9 system markers. Relative gene expression changes for MMP9 system markers in (a) astrocytes, (c) microglia, (e) endothelial cells, and (g) neuronal cells. Data are shown as a fold change from control-treated cells for that time point. \* indicates a *p* value \< .05 and \*\* indicates a *p* value \< .01 compared with control-treated cells for that time point. *p* values for homocysteine-treated comparisons for (b) astrocytes, (d) microglia, (f) endothelial cells, and (h) neuronal cells. Significant differences are shown in bold.

Microglia had slightly increased MMP9 levels at 24 hr, but this was not significant ([Figure 3(c)](#fig3-1759091417742296){ref-type="fig"}). Levels of MMP9 were significantly increased at 72 hr when compared with controls and when compared with 24, 48, and 96 hr homocysteine-treated cells ([Figure 3(d)](#fig3-1759091417742296){ref-type="fig"}). TIMP1 levels were significantly increased at 96 hr when compared with controls and when compared with 48 and 72 hr homocysteine-treated cells.

Endothelial cells treated with homocysteine had significantly increased levels of MMP3 at 48 hr when compared with controls ([Figure 3(e)](#fig3-1759091417742296){ref-type="fig"}). However, MMP9 levels, while slightly increased at 24 hr, were significantly decreased at 48 and 96 hr when compared with 24 hr homocysteine-treated cells ([Figure 3(f)](#fig3-1759091417742296){ref-type="fig"}). Levels were returned to normal at 72 hr. TIMP1 was only slightly increased at 48 hr with no significant changes. Neuronal cells only had slight increases in both MMP9 and TIMP1 at 72 hr with levels returning to normal at 96 hr ([Figure 3(g)](#fig3-1759091417742296){ref-type="fig"} and ([h](#fig3-1759091417742296){ref-type="fig"})).

Astrocytes treated with homocysteine show a trend for decreased aquaporin 4 (AQP4) levels up to 72 hr and then increase again at 96 hr; however, this was not significant when compared with controls ([Figure 4(a)](#fig4-1759091417742296){ref-type="fig"}). Glial fibrillary acidic protein levels increased up to 72 hr and then decreased at 96 hr, but again this was not significant when compared with controls. The adenosine triphosphate (ATP)-sensitive inward rectifier potassium channel 10 (KCNJ10) had significantly increased gene expression levels at 24 hr when compared with controls. However, by 48 and 72 hr, levels were significantly decreased when compared with the 24 hr homocysteine-treated cells ([Figure 4(b)](#fig4-1759091417742296){ref-type="fig"}). Levels of KCNJ10 were significantly increased at 96 hr when compared with 72 hr homocysteine-treated cells. Another potassium channel, potassium calcium-activated channel subfamily M alpha 1 (KCNMA1) was slightly decreased at 72 hr, but was not significant. Figure 4.Cell-specific markers. Relative gene expression changes for cell-specific markers in (a) astrocytes, (c) endothelial cells, and (e) neuronal cells. Data are shown as a fold change from control-treated cells for that time point. \* indicates a *p* value \< .05 and \*\* indicates a *p* value \< .01 compared with control-treated cells for that time point. *p* values for homocysteine-treated comparisons for (b) astrocytes, (d) endothelial cells, and (f) neuronal cells. Significant differences are shown in bold.

Endothelial cells treated with homocysteine showed no changes in platelet endothelial cell adhesion molecule 1 gene expression levels over the 96 hr ([Figure 4(c)](#fig4-1759091417742296){ref-type="fig"}). Claudin-5 levels had increasing levels with a peak at 72 hr. Levels of claudin-5 were significantly decreased at 96 hr when compared with 72 hr homocysteine-treated cells ([Figure 4(d)](#fig4-1759091417742296){ref-type="fig"}). Occludin levels were significantly decreased at 48 hr when compared with controls but levels were significantly higher at 72 hr when compared with 48 and 96 hr homocysteine-treated controls. Collagen Type IV alpha 5 had decreased levels with a peak at 72 hr. Levels were significantly increased at 96 hr when compared with 24, 48, and 72 hr homocysteine-treated cells.

Neuronal cells treated with homocysteine had slight increases in APP and granulin at 48 hr but levels decreased at 72 hr and further decreased at 96 hr ([Figure 4(e)](#fig4-1759091417742296){ref-type="fig"}); however, none of these changes were significant. Both glycogen synthase kinase 3 beta (GSK3β), serine/threonine-protein phosphatase 2 A (PPP2CA), and KCNMA1 had increased gene expression levels up to 72 hr but decreased at 96 hr when compared with 72 hr homocysteine-treated cells ([Figure 4(f)](#fig4-1759091417742296){ref-type="fig"}). KCNJ10 had significantly increased levels at 48 hr when compared with controls and levels were significantly decreased at 72 hr when compared with 48 hr homocysteine-treated cells.

Discussion {#sec11-1759091417742296}
==========

HHcy is a risk factor for both VCID and AD, the two most common forms of dementia. Our lab has developed a mouse model that induces HHcy to model VCID. In this mouse model, we see cognitive deficits, an increase in microglial staining, a proinflammatory phenotype, and a significant increase in microhemorrhages ([@bibr30-1759091417742296]). While we know the overall effect of HHcy on the brain, there is limited information on the cell specific effects of HHcy. We took cell cultures of astrocytes, microglia, endothelial cells, and neuronal cells and treated them with homocysteine to determine gene expression changes specific to each cell type. Astrocytes showed a decrease in two potassium channels and aquaporin 4 with lows at 72 hr. Microglia cells showed an initial increase in proinflammatory markers at 48 hr but then an increase in anti-inflammatory markers at 72 hr. Endothelial cells showed an increase in claudin-5 up to 72 hr but a decrease in occludin at 48 hr. Neurons treated with homocysteine showed an increase in two potassium channels, GSK3β and PPP2CA as well as increases in anti-inflammatory markers with peaks at 72 hr.

Inflammation has been implicated as a possible mechanism for vascular damage in VCID ([@bibr24-1759091417742296]) and induction of HHcy in mice to model VCID has shown a proinflammatory response ([@bibr30-1759091417742296]), which can activate MMPs and lead to vascular breakdown and cognitive impairment. Inflammation has also been implicated in the disease process of AD and our comorbidity mice show a switch from an anti-inflammatory phenotype to a proinflammatory phenotype ([@bibr37-1759091417742296]; [@bibr11-1759091417742296]; [@bibr13-1759091417742296]; [@bibr27-1759091417742296]; [@bibr15-1759091417742296]; [@bibr19-1759091417742296]; [@bibr29-1759091417742296], [@bibr31-1759091417742296]). Both microglia and astrocytes are capable of secreting inflammatory cytokines and proteases ([@bibr6-1759091417742296]; [@bibr10-1759091417742296]) in response to a variety of different stimuli, thus controlling the inflammatory phenotype. When treated with HHcy *in vitro*, microglia produce higher levels of several proinflammatory markers at 48 hr, which is similar to the proinflammatory response seen *in vivo* in our chronic HHcy mouse studies. By 72 hr, however, these levels of proinflammatory markers are reduced and there is an increase in an anti-inflammatory marker. While our mouse models show a proinflammatory phenotype when on diet for 6 months, this cell data suggest that long-term exposure to HHcy would ultimately result in a switch to an anti-inflammatory phenotype. Astrocytes, neurons, and endothelial cells show a limited inflammatory response to HHcy with slight increases in anti-inflammatory markers around 48 and 72 hr. This shows that only microglia, rather than both microglia and astrocytes, are the inflammatory phenotype mediators when HHcy is present.

One of the major proteases involved in tight junction breakdown is MMP9 ([@bibr16-1759091417742296]; [@bibr12-1759091417742296]), which can be activated via inflammation, specifically the proinflammatory cytokines TNFα and IL1β ([@bibr9-1759091417742296]; [@bibr34-1759091417742296]). Our VCID mouse model shows a significant increase in activation of MMP9 as well as increases in TNFα and IL1β, providing a possible mechanism for the increase in microhemorrhages seen in the mouse model ([@bibr30-1759091417742296], [@bibr31-1759091417742296]). Our *in vitro* data show that at 48 hr, astrocytes and endothelial cells are the major sources of MMP9 and MMP3, respectively. The increases seen in the MMP system, in particular MMP9, are parallel to those seen in the mouse model of HHcy. Treatment of individual cell types with homocysteine has provided insight into the major sources of MMP9 at different time points.

The response of cell specific genes to homocysteine can also generate therapeutic targets for treatment of VCID. In astrocytes, AQP4, KCNJ10, and KCNMA1 were decreased, similarly peaking at 72 hr. These potassium channels and AQP4 channel are associated with homeostatic control of potassium buffering, water balance, and are located at the astrocyte end-feet ([@bibr22-1759091417742296]; [@bibr28-1759091417742296]; [@bibr4-1759091417742296]). We have shown a disruption in these channels and other astrocytic end-feet channels in our VCID mouse model ([@bibr32-1759091417742296]). The fact that HHcy can directly influence the expression of these channels was surprising and could highlight unique cellular mechanisms underlying the *in vivo* astrocytic disruptions previously observed. The decreases seen in these astrocytic end-feet genes could lead to disruption of the neurovascular unit and blood flow to these damaged areas, contributing to the cognitive decline seen in our mouse model. Endothelial cells also play a major role in the neurovascular unit by maintaining the tight junctions that make up the blood--brain barrier. Interruption of these tight junctions and consequently the blood--brain barrier can lead to microhemorrhages that damage the surrounding brain tissue. Treatment of endothelial cells showed a significant decrease in occludin, a major tight junction protein, at 48 hr. Homocysteine also induced an increase in claudin-5 gene expression levels which could compensate for the lowered occludin levels. However, while the gene expression of claudin-5 is increased, it may not equate to increased protein levels or even localization of the protein to the tight junctions. These disruptions in tight junctions could provide another mechanism via which HHcy causes microhemorrhages and cognitive decline by directly affecting tight junction gene expression levels, as opposed to our previous hypothesis that this was mediated by MMP degradation of tight junctions. HHcy is also a risk factor for AD ([@bibr33-1759091417742296]), which is characterized by amyloid plaques and tangles made of hyperphosphorylated tau ([@bibr3-1759091417742296]). APP and granulin, which are associated with AD and frontotemporal dementia, respectively, are not altered in neuronal cells when exposed to homocysteine, suggesting an alternate mechanism in which HHcy increases the risk of AD. There are alterations in the tau kinase GSK3β as well as changes in the tau phosphatase PPP2CA in the neuronal cells exposed to homocysteine. While these increases may cancel each other out, the gene expression changes may not lead to equal changes in protein levels or even protein activity for each. Further studies would be required to determine these changes in protein levels or activity, and provide a possible link between HHcy and AD. We have not observed significant tau changes in the mouse model of HHcy, but these data indicate that a more careful examination of tau state may be required.

The responses of specific cell types to homocysteine provide a starting point for future studies that could identify a wide variety of targets for AD and VCID therapeutics. For example, targeting microglia to reduce the release of proinflammatory cytokines could help reduce MMP9 activation leading to a decrease in tight junction breakdown. Astrocytic end-feet present another possible target to help reduce neurovascular damage and cognitive decline. GSK3β or PPP2CA could also be targeted to help reduce the risk of developing tauopathies in HHcy patients. The gene changes seen here have the potential to be biomarkers for VCID as well, and when compared with gene changes seen in AD, possible biomarkers for patients with VCID and AD. Other future studies would include cell specific functional changes in response to HHcy and interactions between cell lines when homocysteine is present.

Summary {#sec12-1759091417742296}
=======

Whether through genetic mutation or low levels of several B vitamins, increasing the levels of homocysteine in the brain can lead to gene expression changes in the major cell types of the brain, which can contribute to vascular cognitive impairment.
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